These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24624702)

  • 1. [Hepatitis C: cost of eradication ].
    Nau JY
    Rev Med Suisse; 2014 Jan; 10(415):306-7. PubMed ID: 24624702
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hepatitis B and hepatitis C, a high stake for public health: how to reconcile health cost control and public health expenses?].
    Allerg Immunol (Paris); 1997 Sep; 29(7):215-8. PubMed ID: 9432191
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapy of hepatitis C: cost-effectiveness analysis.
    Koff RS
    Hepatology; 1997 Sep; 26(3 Suppl 1):152S-155S. PubMed ID: 9305681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achieving hepatitis C elimination in Taiwan-Overcoming barriers by setting feasible strategies.
    Wu GH; Pwu RF; Chen SC
    J Formos Med Assoc; 2018 Dec; 117(12):1044-1045. PubMed ID: 30449458
    [No Abstract]   [Full Text] [Related]  

  • 6. A Guide to the Economics of Hepatitis C Virus Cure in 2017.
    Linas BP; Nolen S
    Infect Dis Clin North Am; 2018 Jun; 32(2):447-459. PubMed ID: 29778265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A world without hepatitis C.
    Ryder S; Dillon J
    Health Serv J; 2014 May; 124(6397):21-3. PubMed ID: 25033511
    [No Abstract]   [Full Text] [Related]  

  • 8. [Should hepatitis C be screened? Socioeconomic analysis of different screening strategies for chronic hepatitis C in French population].
    Rotily M; Loubière S; Nixon J; Bourlière M; Halfon P; Moatti JP
    Gastroenterol Clin Biol; 1997; 21(1 Pt 2):S33-40. PubMed ID: 9161512
    [No Abstract]   [Full Text] [Related]  

  • 9. Eliminating hepatitis C.
    Burki T
    Lancet Infect Dis; 2019 Mar; 19(3):246-247. PubMed ID: 30833063
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatitis C Elimination in Rwanda: Progress, Feasibility, and Economic Evaluation.
    Zhong H; Aaron A; Hiebert L; Serumondo J; Zhuo Y; Adee M; Rwibasira GN; Ward JW; Chhatwal J
    Value Health; 2024 Jul; 27(7):918-925. PubMed ID: 38492923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leaving no one behind: Towards equitable global elimination of hepatitis C.
    Dahl EH; Zahid H; Aslam K; Jafri W
    J Glob Health; 2020 Jun; 10(1):010308. PubMed ID: 32257136
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of acute hepatitis C in HIV coinfection: Is this a chance for achieving microelimination?
    Rockstroh J; Boesecke C
    United European Gastroenterol J; 2019 May; 7(4):465-466. PubMed ID: 31065363
    [No Abstract]   [Full Text] [Related]  

  • 13. Universal Hepatitis C Eradication Prior to Liver Transplantation: We Can Do It, but Should We?
    Brown RS
    Am J Transplant; 2015 Jul; 15(7):1741-2. PubMed ID: 26086299
    [No Abstract]   [Full Text] [Related]  

  • 14. [Medico-economic assessment of the therapeutic management of patients with hepatitis C].
    Loubière S; Rotily M; Moatti JP
    Gastroenterol Clin Biol; 2000 Nov; 24(11):1047-51. PubMed ID: 11139674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of a hypothetical hepatitis C vaccine compared to antiviral therapy.
    Massad E; Coutinho FA; Chaib E; Burattini MN
    Epidemiol Infect; 2009 Feb; 137(2):241-9. PubMed ID: 18631422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Analysis of National Program for Hepatitis C Elimination, Israel, 2023
    Dadon Y; Mimouni FB; Toren A; Morgenstern T; Barak L; Mendlovic J
    Emerg Infect Dis; 2024 Oct; 30(10):2070-2078. PubMed ID: 39320161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?
    van de Vooren K; Curto A; Garattini L
    Eur J Health Econ; 2015 May; 16(4):341-5. PubMed ID: 25407841
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
    Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
    Eur J Public Health; 2009 Jun; 19(3):245-53. PubMed ID: 19196737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investment cases for hepatitis C: never more important.
    Wingrove C; Hicks J; Regan S; Wang S
    Lancet Gastroenterol Hepatol; 2021 May; 6(5):340-341. PubMed ID: 33857440
    [No Abstract]   [Full Text] [Related]  

  • 20. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis.
    Plunkett BA; Grobman WA
    Am J Obstet Gynecol; 2005 Apr; 192(4):1153-61. PubMed ID: 15846195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.